Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - LM-302 "CLDN18.2 ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS2025.08.19
-
Cash Dividend Announcement for Equity Issuer2025.08.19
-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 20252025.08.18
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3142 “BcL-xL PROTAC”ACCEPTED BY NMPA2025.08.12
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3122 "PARP1 INHIBITOR" ACCEPTED BY NMPA2025.08.11
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY THE NMPA2025.08.07
-
VOLUNTARY ANNOUNCEMENT - ROVADICITINIB TABLET "JAK/ROCK INHIBITOR" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS2025.08.06
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINCAL TRIAL OF TQC3302 "ICS/LAMA/LABA SOFT MIST INHALATION FORMULATION" APPROVED BY NMPA2025.08.05